<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01575041</url>
  </required_header>
  <id_info>
    <org_study_id>KaNa-trial</org_study_id>
    <nct_id>NCT01575041</nct_id>
  </id_info>
  <brief_title>The Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function</brief_title>
  <acronym>KaNa</acronym>
  <official_title>Study on the Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function in Untreated (Pre)Hypertensive Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wageningen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of (1) increased sodium intake and (2) increased potassium intake on&#xD;
      blood pressure, vascular function and renal function in untreated (pre)hypertensive subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo controlled cross-over feeding study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Endothelium-dependent flow-mediated dilation comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.</measure>
    <time_frame>Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Ultra-sonography (brachial artery) + Picus system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.</measure>
    <time_frame>Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Includes:&#xD;
Office BP (Dinamap, 4 consecutive measurements with 2-min intervals) ABPM (Spacelab; 1x24h, at baseline, week 5, week 9, week 13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse Wave Velocity comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.</measure>
    <time_frame>Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Device: SphygmoCor (tonometry)&#xD;
Parameters: Pulse Wave Velocity and at baseline, week 5, week 9 and week 13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vasomotion comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.</measure>
    <time_frame>Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Device: PeriFlux 5000 (Perimed, Sweden0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biomarkers of endothelial function comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.</measure>
    <time_frame>Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Plasma analysis of endothelin-1, ADMA, MCP-1, sVCAM-1, sICAM-1, sE-selectin, sTM, CRP, SAA, IL-6, IL-8, TNF-α, vWF, nitric oxide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.</measure>
    <time_frame>Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>eGFR, serum creatinine (at screening also used as safety parameter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cardiovascular parameters in plasma comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.</measure>
    <time_frame>Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, insulin and glucose (at screening also used as safety parameter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function parameters</measure>
    <time_frame>Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Montoring liver function parameters for safety: includes ALAT, ASAT and ɣ-GT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour urinary mineral excretions</measure>
    <time_frame>Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Sodium and potassium (as compliance markers)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour excretion of protein, albumin and creatinine</measure>
    <time_frame>Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>In addition, protein is assessed in spot urine during screening using a dipstick test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Every day</time_frame>
    <description>Patient diary for occasions of illness, hospitalizations, medication use and other information on potential side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric measurements</measure>
    <time_frame>Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Body weight (weekly), height (only at baseline), waist circumference (baseline and every 4 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Dinamap, 4 consecutive measurements with 2-min intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food frequency questionnaire</measure>
    <time_frame>Screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse Wave Analysis comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.</measure>
    <time_frame>Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)</time_frame>
    <description>Device: SphygmoCor (tonometry)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypertension</condition>
  <condition>Blood Pressure</condition>
  <condition>Vascular Function</condition>
  <condition>Renal Function</condition>
  <arm_group>
    <arm_group_label>Sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium</intervention_name>
    <description>Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Potassium</arm_group_label>
    <arm_group_label>Sodium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium</intervention_name>
    <description>Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.</description>
    <arm_group_label>Potassium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  (Pre)hypertension, defined as office SBP: 130-159 mmHg;&#xD;
&#xD;
          -  No use of antihypertensive, lipid-lowering, anticoagulant or other cardiovascular&#xD;
             medication;&#xD;
&#xD;
          -  Age at start of the ≥ 40 years;&#xD;
&#xD;
          -  Apparently healthy:&#xD;
&#xD;
               -  No reported current or previous metabolic diseases&#xD;
&#xD;
               -  No history of cardiovascular diseases&#xD;
&#xD;
               -  No history of renal, liver or thyroid diseases&#xD;
&#xD;
               -  No history of gastrointestinal diseases&#xD;
&#xD;
               -  No diabetes mellitus&#xD;
&#xD;
               -  Fasting laboratory parameters within normal range: renal function (serum&#xD;
                  creatinine, ureum), liver function (ALAT, ASAT, ɣ-GT) and serum glucose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index &gt; 40 kg/m²;&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Secondary hypertension;&#xD;
&#xD;
          -  Weight loss or weight gain of 5 kg or more during the last 2 months;&#xD;
&#xD;
          -  Usage of non-steroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen) and not&#xD;
             able or willing to stop taking them from at least 4 weeks prior to the study.&#xD;
&#xD;
          -  Medical treatment that may affect blood pressure and not able (or willing) to stop&#xD;
             taking them;&#xD;
&#xD;
          -  Women taking oral contraceptives or estrogen replacement therapy&#xD;
&#xD;
          -  Taking nutritional supplements and unwilling to discontinue;&#xD;
&#xD;
          -  Women lactating, pregnant or intend to become pregnant during study;&#xD;
&#xD;
          -  Reported dietary habits: medically prescribed diet, slimming diet;&#xD;
&#xD;
          -  Reported alcohol consumption &gt; 21 units/w (female subjects) or &gt;28 units/w (male&#xD;
             subjects);&#xD;
&#xD;
          -  Unable or unwilling to consume one meal every workday at the university, or to consume&#xD;
             the prescribed study diet for 13 weeks;&#xD;
&#xD;
          -  Problems with consuming the supplements or following the study guidelines;&#xD;
&#xD;
          -  Unwilling to undergo home or office blood pressure measurements;&#xD;
&#xD;
          -  Recent blood donation i.e. 1 month (male subjects) or 2 months (female subjects) prior&#xD;
             to the study and planned donation during the study period;&#xD;
&#xD;
          -  Reported intense sporting activities &gt; 10 h/w;&#xD;
&#xD;
          -  Not agreeing to be informed about unexpected and medically relevant personal&#xD;
             test-results&#xD;
&#xD;
          -  Participation in another biomedical trial less than 2 months before the start of the&#xD;
             study or at the same time;&#xD;
&#xD;
          -  No informed consent signed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna M Geleijnse, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wageningen University, Division of Human Nutrition</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wageningen University</name>
      <address>
        <city>Wageningen</city>
        <zip>6703 HD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.hne.wur.nl/UK</url>
    <description>Website of Division of Human Nutrition, Wageningen University, The Netherlands</description>
  </link>
  <link>
    <url>http://www.tifn.nl</url>
    <description>Website of the Top Institute Food and Nutrition, Wageningen, The Netherlands</description>
  </link>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>March 20, 2012</study_first_submitted>
  <study_first_submitted_qc>April 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2012</study_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sodium</keyword>
  <keyword>salt</keyword>
  <keyword>potassium</keyword>
  <keyword>blood pressure</keyword>
  <keyword>flow-mediated dilatation</keyword>
  <keyword>endothelial function</keyword>
  <keyword>renal function</keyword>
  <keyword>controlled feeding study</keyword>
  <keyword>dietary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

